Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China

18 9 月, 2025

One Min Read

15 Views

原文: https://finance.yahoo.com/news/summit-therapeutics-inc-smmt-faces-144114449.html

Last Update: 18 9 月, 2025

Written By

Other Articles

Previous

Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa

Next

Integer Holdings Corporation (ITGR) Posts 11% Q2 Sales Growth Despite Stock Hitting 52-Week Low

Related Posts

Powerball jackpot soars to $1.3 billion. Here’s what the winner will take home after taxes.

1 Min Read

What is force-placed car insurance, and when do lenders require it?

1 Min Read

Do you need collateral for a personal loan? See when it might help.

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept